Head & Neck Cancer

Latest News

Prognostic Factors Linked With Poor Locoregional Control in Tongue Cancer | Image Credit: © freshidea - stock.adobe.com.
Prognostic Factors Linked With Poor Locoregional Control in Tongue Cancer

March 5th 2024

Patients with factors such as lymphovascular space invasion or positive glossectomy specimen margins may be considered for adjuvant radiotherapy to optimize disease control of tongue squamous cell carcinoma.

 Radiation Therapy Plus Chemo Yielded Increased Efficacy in HPV+ Oropharynx Cancer
Radiation Therapy Plus Chemo Yielded Increased Efficacy in HPV+ Oropharynx Cancer

March 4th 2024

Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.
Pembrolizumab/Lenvatinib Combo Shows Mixed Results in Recurrent/Metastatic HNSCC

March 1st 2024

The FDA grants clearance to an oral immobilization stent designed to redirect radiation to the target tumor area for patients with head and neck cancer.
FDA Clears Oral Stent Solution for Radiotherapy in Head and Neck Cancer

January 22nd 2024

After observing a prevalence of thyroid cancer among transgender female patients through clinical observation, a study was prompted by clinicians in order to determine if this is an issue in a larger population.
Thyroid Cancer Rates Are Higher Among Transgender Female Veterans

October 29th 2023

More News


Site Logo

Can Rash Associated With HER1/EGFR Inhibition Be Used as a Marker of Treatment Outcome?

November 2nd 2003

Rash is a class effect of HER1/epidermal growth factor receptor(EGFR)-targeted agents, and has occurred with high frequency and ina dose-dependent manner in clinical trials of these agents in cancerpatients. Analysis of phase II trials of erlotinib (Tarceva) in non–smallcelllung cancer, head and neck cancer, and ovarian cancer shows asignificant association between rash severity and objective tumor response.Rash severity was highly significantly associated with survivalin patients with non–small-cell lung cancer receiving erlotinib; mediansurvival in patients with no rash was 46.5 days, compared with257 days in those with grade 1 rash (P < .0001) and 597 days in thosewith grade 2/3 rash (P < .0001). Similarly, for the combined non–smallcelllung cancer, head and neck cancer, and ovarian cancer studies,median survival in patients with no rash was 103 days, compared with191 days in those with grade 1 rash (P = .0001) and 266 days in thosewith grade 2/3/4 rash (P = .0001). Similar findings have been madewith cetuximab (Erbitux) and in some settings with gefitinib (Iressa).The strong association of rash severity with response/survival suggeststhat rash may serve as a marker of response to erlotinib treatment andmay be used to guide treatment to obtain optimal response. Dosingerlotinib at the maximum tolerated dose, which is associated with morefrequent and more severe rash, may improve response rates and survivaldurations. Further study of the potentially important associationbetween rash and outcome of treatment with EGFR-targeted agents isneeded.